Hoth Therapeutics, Inc. (HOTH)
- Previous Close
1.1600 - Open
1.1400 - Bid 0.8064 x 200
- Ask 1.4500 x 200
- Day's Range
1.0900 - 1.1400 - 52 Week Range
0.9900 - 3.3700 - Volume
28,275 - Avg. Volume
435,041 - Market Cap (intraday)
5.329M - Beta (5Y Monthly) 0.79
- PE Ratio (TTM)
-- - EPS (TTM)
-1.8800 - Earnings Date Aug 9, 2024 - Aug 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
4.67
Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It develops HT-001, a topical formulation in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; and HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases. The company is also developing BioLexa Platform, a proprietary, patented, drug compound platform in Phase I clinical trial for the treatment of eczema; and HT-005 for treating patients with lupus. The company has license agreements with the George Washington University; Isoprene Pharmaceuticals, Inc.; Virginia Commonwealth University; the North Carolina State University; Chelexa BioSciences, Inc. and the University of Cincinnati; Zylö Therapeutics, Inc.; and Voltron Therapeutics, Inc. It also has a research collaboration agreement with Weill Cornell Medicine to develop HT-003. Hoth Therapeutics, Inc. was incorporated in 2017 and is headquartered in New York, New York.
hoththerapeutics.comRecent News: HOTH
Performance Overview: HOTH
Trailing total returns as of 6/7/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: HOTH
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: HOTH
Valuation Measures
Market Cap
5.33M
Enterprise Value
-2.19M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.68
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-43.01%
Return on Equity (ttm)
-78.21%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-7.7M
Diluted EPS (ttm)
-1.8800
Balance Sheet and Cash Flow
Total Cash (mrq)
7.56M
Total Debt/Equity (mrq)
0.62%
Levered Free Cash Flow (ttm)
-5.39M